#China #Beijing #Drug Discovery #Tsingke Biotech #Antibody Solutions

Accelerating Drug Development with Tsingke Biotech

At the PEGS Europe 2025 event, held in Lisbon, Tsingke Biotech, a pioneering name in biopharmaceutical innovation, showcased its advanced services for rapid protein and antibody production. The company boasts an impressive capability to generate proteins in as little as three days and antibodies in just seven days, marking a significant advancement for biopharma developers striving to expedite drug discovery processes.

The Speed of Innovation

Tsingke's cutting-edge approach integrates state-of-the-art gene synthesis, automated expression, and purification technologies to produce proteins swiftly and effectively across six different expression systems. These systems include E. coli, Bacillus subtilis, yeast, insect cells, mammalian systems, and cell-free methods, with a remarkable success rate of 95% for overall protein expression. This versatility empowers researchers to efficiently produce both simple and complex proteins, where simpler proteins can be generated in three days and complex proteins and antibodies within a timeframe of 7 to 14 days.

Transforming Antibody Development

Tsingke Biotech's Single-B Cell Antibody Discovery Service is a game-changer in the industry. Traditional methods often take between one to two months to develop antibodies using hybridoma technology. In stark contrast, Tsingke's innovative service preserves the natural VH/VL pairing and allows for the generation of high-affinity antibodies, significantly reducing the time to results to only 8 to 10 weeks. The use of FACS technology further enhances the efficiency and quality of the antibody development process.

For antibody production, Tsingke utilizes Expi293 and CHO-K1 systems, delivering milligram-scale yields in just seven days and gram-scale yields in two weeks. The company reports an average production exceeding 300 mg/L, and offers a diverse range of antibody formats, including VHH-His and VHH-Fc, catering to a variety of research demands.

Industry Engagement and Future Prospects

The attention Tsingke Biotech garnered at the PEGS Summit was remarkable. Industry professionals and companies engaged in substantive discussions with Tsingke's representatives, exploring exciting potential collaborations. This interest underscores the heightened demand for rapid, innovative solutions in protein and antibody production.

According to Nan Zhang, Global Marketing Manager at Tsingke Biotech, "PEGS is key for professionals engaged in protein and antibody engineering. Our service's combination of speed, customization, and quality aligns perfectly with the growing need for quicker drug development in the biopharma industry." Tsingke's commitment to excellence is reflected in its ISO 13485-certified facilities equipped with state-of-the-art Class 100,000 cleanroom environments, ensuring adherence to the highest quality standards and smooth transitions from research-grade applications to GLP/GMP-compliant workflows.

About Tsingke Biotech

Beijing Tsingke Biotech Co., Ltd. is at the forefront of biotechnology, offering an extensive range of solutions targeted at research and therapeutic development. With a focus on molecular biology, genetics, and protein science, the company specializes in custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (AAV, LV, AdV). Tsingke's certified production environments guarantee consistency in quality and reliability, while advanced automation, backed by a global scientific team, facilitates innovation in drug discovery, functional genomics, and genetic engineering.

To stay updated on Tsingke Biotech's latest advancements and offerings, follow their journey on LinkedIn. With a dedication to empowering researchers globally, Tsingke is undoubtedly accelerating the pace of biomanufacturing solutions in the biotechnology sector.